Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

479

Participants

Timeline

Start Date

March 4, 2020

Primary Completion Date

March 5, 2030

Study Completion Date

March 4, 2032

Conditions
Prostate Cancer
Interventions
DRUG

AMG 509

AMG 509 administered as an IV infusion (Parts 1, 3, 4 and 5) or SC injection (Part 2).

DRUG

Abiraterone

Abiraterone administered as oral tablets.

DRUG

Enzalutamide

Enzalutamide administered as oral tablets.

Trial Locations (54)

1011

RECRUITING

Centre Hospitalier Universitaire Vaudois, Lausanne

2050

RECRUITING

Chris OBrien Lifehouse, Camperdown

3168

RECRUITING

Monash Medical Centre, Clayton

6500

RECRUITING

Istituto Oncologico della Svizzera Italiana, Bellinzona

7000

RECRUITING

Kantonsspital Graubuenden, Chur

9007

RECRUITING

Kantonsspital Sankt Gallen, Sankt Gallen

10002

RECRUITING

National Taiwan University Hospital, Taipei

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

15232

RECRUITING

University of Pittsburgh Medical Center, Pittsburgh

19107

RECRUITING

Thomas Jefferson University, Philadelphia

22031

RECRUITING

Virginia Cancer Specialists PC, Fairfax

23502

RECRUITING

Virginia Oncology Associates, Norfolk

27103

RECRUITING

Wake Forest University Health Sciences, Winston-Salem

27710

RECRUITING

Duke University, Durham

28040

RECRUITING

Hospital Clinico San Carlos, Madrid

28041

RECRUITING

Hospital Universitario 12 de Octubre, Madrid

29605

COMPLETED

Prisma Health Upstate, Greenville

30322

RECRUITING

Emory University, Atlanta

31008

RECRUITING

Clinica Universidad de Navarra, Pamplona

33305

RECRUITING

Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation, Taoyuan District

37203

RECRUITING

United States Oncology Regulatory Affairs Corporate Office, Nashville

45147

RECRUITING

Universitaetsklinikum Essen, Essen

45242

RECRUITING

Oncology Hematology Care Incorporated, Cincinnati

46202

RECRUITING

Indiana University, Indianapolis

48149

RECRUITING

Universitaetsklinikum Muenster, Münster

57104

RECRUITING

Sanford Oncology Clinic and Pharmacy, Sioux Falls

63110

RECRUITING

Washington University, St Louis

66204

RECRUITING

Alliance for Multispecialty Research, Merriam

69120

RECRUITING

Universitaetsklinikum Heidelberg, Heidelberg

70112

COMPLETED

Tulane Medical Center, New Orleans

75063

RECRUITING

US Oncology Research Investigational Products Center, Irving

77030

RECRUITING

University of Texas MD Anderson Cancer Center, Houston

80012

RECRUITING

Rocky Mountain Cancer Centers, Aurora

81675

RECRUITING

Klinikum rechts der Isar der TUM, München

84107

RECRUITING

Intermountain Medical Center, Murray

91010

RECRUITING

City of Hope National Medical Center, Duarte

92835

RECRUITING

Providence Saint Jude Medical Center, Fullerton

94158

RECRUITING

University of California San Francisco, San Francisco

98109

RECRUITING

Fred Hutchinson Cancer Center, Seattle

200032

RECRUITING

Fudan University Shanghai Cancer Centre, Shanghai

314408

RECRUITING

Zhejiang Provincial Peoples Hospital, Hangzhou

330006

RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

510060

RECRUITING

Sun Yat-sen University, Cancer Center, Guangzhou

06520

RECRUITING

Yale New Haven Hospital, New Haven

277-8577

RECRUITING

National Cancer Center Hospital East, Kashiwa-shi

236-0004

RECRUITING

Yokohama City University Hospital, Yokohama

135-8550

RECRUITING

The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku

1500-650

RECRUITING

Hospital da Luz, SA, Lisbon

1649-035

RECRUITING

Unidade Local de Saude de Santa Maria, EPE - Hospital de Santa Maria, Lisbon

4200-072

RECRUITING

Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE, Porto

03080

RECRUITING

Seoul National University Hospital, Seoul

138-736

RECRUITING

Asan Medical Center, Seoul

08035

RECRUITING

Hospital Universitari Vall d Hebron, Barcelona

08036

RECRUITING

Hospital Clinic i Provincial de Barcelona, Barcelona

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

BeiGene

INDUSTRY

collaborator

BeOne (China only)

UNKNOWN

lead

Amgen

INDUSTRY

NCT04221542 - Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter